Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent

R. J. Firpi, T. T. Tran, P. Flores, N. Nissen, S. Colquhoun, C. Shackleton, P. Martin, J. M. Vierling, F. F. Poordad

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. Method: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. Conclusion: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.

Original languageEnglish
Pages (from-to)1033-1039
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Issue number9
StatePublished - 1 May 2004
Externally publishedYes


Dive into the research topics of 'Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent'. Together they form a unique fingerprint.

Cite this